The global nasal spray market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Nasal spray is a liquid form of concentrated medicine that is dispensed through a compact container/bottle into the nose for the treatment of the nasal congestion problem. The active ingredient's intended action can be local or systemic in nature. Nasal spray sprays are designed to be deposited in the nasal or pharyngeal region. The rising prevalence of asthma and COPD, as well as the low cost of these sprays are propelling the market growth. Asthma is the most common chronic condition among children globally, as per the World Health Organization (WHO) research published in 2019. Asthma affected around 235 million people across the globe in 2019. Low- and lower-middle-income nations account for more than 80% of asthma-related mortalities. 

The risk factor for developing asthma includes inhaled substances and particles that create allergic reactions or irritate the airways whereas risk factor leading to the cause of COPD includes tobacco smoke or second-hand smoke, exposure to indoor or outdoor air pollution, dusts and fumes, and long-term asthma.  Furthermore, as per the study conducted by National Health and Planning Commission in 2019, 30 million people in China suffered from asthma and only 28% of the people with asthma have their condition under control. This, in turn, is driving the demand for nasal sprays for the management of asthma and COPD. 

Some key players operating in the market include AstraZeneca plc, Novartis International AG, and Teva Pharmaceutical Industries Ltd., among others. These players are eyeing on strengthening their position in the market by adopting various strategies as mergers and acquisitions, partnerships, collaborations, new product launch and development in the existing product portfolio, and so on. For instance, in February 2022, Glenmark Ltd. and Canadian biotech firm SaNOtize Research and Development Corp launched its Nitric Oxide Nasal Spray (NONS) under the brand name FabiSpray in India. It can be used for the treatment of adult patients with COVID-19 who have a high risk of progression of the disease.

Market Coverage

    • The market number available for – 2020-2027

    • Base year- 2020

    • Forecast period- 2021-2027

    • Segment Covered- 

o By Product

o By Application

• Regions covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

    • Competitive Landscape: AstraZeneca plc, Novartis International AG, and Teva Pharmaceutical Industries Ltd., among others.

Key questions addressed by the report

    • What is the market growth rate?

    • Which segment and region dominate the market in the base year?

    • Which segment and region will project the fastest growth in the market?

    • How COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

    • Who is the leader in the market?

    • How are players addressing challenges to sustain growth?

    • Where is the investment opportunity?

Global Nasal Spray Market Report by Segment

By Product

    • Bronchodilators

    • Corticosteroids

    • Combination

    • Decongestant

    • Others

By Application

    • Asthma

    • COPD

    • Allergic Rhinitis

    • Others

Global Nasal Spray Market Report by Region

North America       

    • US

    • Canada

Europe

    • Germany

    • UK

    • France

    • Spain

    • Italy

    • Rest of Europe

Asia-Pacific    

    • China

    • Japan

    • India

    • Rest of Asia-Pacific

Rest of the World

    • Latin America

    • Middle East and Africa